2020年 業績

  1. 1.Yuki Ozaki, Satoshi Muto, Hironori Takagi, Masayuki Watanabe, Takuya Inoue, Mitsuro Fukuhara, Takumi Yamaura, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Ohsugi, Mika Hoshino, Yutaka Shio, Daisuke Tanaka, Hideaki Nanamiya, Jun-Ichi Imai, Takao Isogai, Shinya Watanabe, Hiroyuki Suzuki. Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer. Cancer immunology, immunotherapy. 69(1): 127-134, 2020
  2. 2.Yuki Matsumura, Na Li, Hanan Alwaseem, Odelya E Pagovich, Ronald G Crystal, Matthew B Greenblatt, Katie M Stiles. Systemic Adeno-Associated Virus-Mediated Gene Therapy Prevents the Multiorgan Disorders Associated with Aldehyde Dehydrogenase 2 Deficiency and Chronic Ethanol Ingestion. Human gene therapy. 31(3-4): 163-182, 2020
  3. 3.Takumi Yamaura, Satoshi Muto, Hayato Mine, Hironori Takagi, Masayuki Watanabe, Yuki Ozaki, Takuya Inoue, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroyuki Suzuki. Genetic alterations in epidermal growth factor receptor-tyrosine kinase inhibitor-naïve non-small cell lung carcinoma. Oncology letters. 19(6): 4169-4176, 2020
  4. 4.Takeo Hasegawa, Hiroyuki Suzuki, Jiro Abe, Akira Sakurada, Chiaki Endo, Nobuyuki Sato, Tohru Hasumi, Hiroyuki Deguchi, Hiroyuki Oura, Satomi Takahashi, Hajime Saito, Hidetaka Uramoto, Motoyasu Sagawa, Yoshinori Okada. A phase 2 study of adjuvant carboplatin plus S-1 followed by maintenance S-1 therapy for patients with completely resected stage II/IIIA non-small cell lung cancer—Japanese Northern East Area Thoracic Surgery Study Group JNETS1302 study. Journal of Thoracic Disease. 12(7), 2020
  5. 5.Wungki Park, Laura Mezquita, Naoyuki Okabe, Young Kwang Chae, Deukwoo Kwon, Diana Saravia, Edouard Auclin, David Planchard, Caroline Caramella, Roberto Ferrara, Sarita Agte, Michael Oh, Raja Mudad, Mohammad Jahanzeb, Hiroyuki Suzuki, Benjamin Besse, Gilberto Lopes. Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. British journal of cancer. 122(3): 340-347, 2020
  6. 6.Ryo Morita, Kyoichi Okishio, Junichi Shimizu, Haruhiro Saito, Hiroshi Sakai, Young Hak Kim, Osamu Hataji, Makiko Yomota, Makoto Nishio, Keisuke Aoe, Osamu Kanai, Toru Kumagai, Kayoko Kibata, Hiroaki Tsukamoto, Satoshi Oizumi, Daichi Fujimoto, Hiroshi Tanaka, Keiko Mizuno, Takeshi Masuda, Toshiyuki Kozuki, Takashi Haku, Hiroyuki Suzuki, Isamu Okamoto, Hirotoshi Hoshiyama, Junya Ueda, Yuichiro Ohe. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan. Lung Cancer. 140: 8-18, 2020
  7. 7.Hiroshi Yokouchi, Hiroshi Nishihara, Toshiyuki Harada, Shigeo Yamazaki, Hajime Kikuchi, Satoshi Oizumi, Hidetaka Uramoto, Fumihiro Tanaka, Masao Harada, Kenji Akie, Fumiko Sugaya, Yuka Fujita, Kei Takamura, Tetsuya Kojima, Mitsunori Higuchi, Osamu Honjo, Yoshinori Minami, Naomi Watanabe, Masaharu Nishimura, Hiroyuki Suzuki, Hirotoshi Dosaka-Akita, Hiroshi Isobe. Detection of somatic TP53 mutation in surgically resected small-cell lung cancer by targeted exome sequencing: association with longer relapse-free survival. Heliyon. 6(7): e04439, 2020
  8. 8.Kyoichi Okishio, Ryo Morita, Junichi Shimizu, Haruhiro Saito, Hiroshi Sakai, Young Hak Kim, Osamu Hataji, Makiko Yomota, Makoto Nishio, Keisuke Aoe, Osamu Kanai, Toru Kumagai, Kayoko Kibata, Hiroaki Tsukamoto, Satoshi Oizumi, Daichi Fujimoto, Hiroshi Tanaka, Keiko Mizuno, Takeshi Masuda, Toshiyuki Kozuki, Takashi Haku, Hiroyuki Suzuki, Isamu Okamoto, Hirotoshi Hoshiyama, Nobumichi Yada, Yuichiro Ohe. Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR). ESMO open. 5(4): e000656, 2020
  9. 9.Hiroyuki Minemura, Hiroshi Moriya, Hisao Imai, Tomohide Sugiyama, Yutaka Yamada, Mitsunori Higuchi, Kyoichi Kaira, Yuki Ozaki, Kenya Kanazawa, Hiroshi Yokouchi, Takashi Kasai, Takayuki Kaburagi, Hiroyuki Suzuki, Koichi Minato, Yoko Shibata. Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab. Thoracic cancer. 11(12): 3521-3527, 2020
  10. 10.Meredith L Sosulski, Katie M Stiles, Esther Z Frenk, Fiona M Hart, Yuki Matsumura, Bishnu P De, Stephen M Kaminsky, Ronald G Crystal. Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin. JCI insight. 5(15): e135951, 2020
  11. 11.Satoshi Muto, Yuki Ozaki, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Yutaka Shio, Yuko Hashimoto, Hiroyuki Suzuki. Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR-TKIs plus Bevacizumab: A Case Report. Case reports in oncology. 13(3): 1387-1392, 2020
  12. 12.Mitsunori Higuchi, Hitoshi Yamada, Kakeru Machino, Ikuro Oshibe, Nobutoshi Soeta, Takuro Saito, Hidetaka Uramoto, Sohsuke Yamada, Hiroshi Hojo, Hiroyuki Suzuki. Successful Multidisciplinary Treatment for Aggressive Primary Pulmonary Undifferentiated Pleomorphic Sarcoma. Case reports in oncology. 13(1):385-391, 2020
  13. 13.Mitsunori Higuchi, Hiroyuki Suzuki. Current status and prospect of medical and surgical management for thoracic empyema. Current Challenges in Thoracic Surgery (CCTS). 2:39, 2020
  14. 14.樋口光徳, 渡部和也, 齋藤拓朗, 渡部晶之, 鈴木弘行. 血清SCC抗原の異常高値が測定法によって乖離した胸腺腫の1手術例. 日本呼吸器外科学会雑誌. 34(7):740-745, 2020
  15. 15.見城明, 丸橋繁, 遠藤俊吾, 鈴木弘行. 特別企画(6)｢外科医にとっての働き方改革とは｣ 5. 外科医の働き方改革: 特定行為研修修了者の活用に向けた課題と対応策. 日本外科学会雑誌. 121(1): 102-104, 2020
  16. 16.鈴木弘行. 本学発信―学術研究成果・新発見等紹介 (3) 肺癌腫瘍内遺伝子異常数が肺癌の術後予後に与える影響の解明. 福島県立医科大学医学部同窓会報「光が丘」. 49: 50-51, 2020
  17. 17.鈴木弘行. パンダハウスを支える皆様へたくさんの感謝を！パンダハウスNews Letter. 10: 2, 2020
  18. 18.鈴木弘行. 医師の働き方改革〜今後の方向性と課題〜. 福島県立医科大学大学医師会会報. 147: 1, 2020
  19. 19.鈴木弘行. 編集後記. 日本免疫治療学会誌(JRAI Report). 8: 36, 2020
  20. 20.鈴木弘行. 巻頭言 コロナ禍に想う－野口英世と肺癌治療の進歩－. 気管支学. 42(6): 477-478, 2020
  21. 21.鈴木弘行. 特集 進行期肺癌治療への道～がんゲノム医療と免疫プレシジョン医療の接点～免疫チェックポイント阻害薬の進化: 複合免疫療法 ｢周術期治療としての免疫チェックポイント阻害薬の効果｣. 呼吸器ジャーナル. 68(3): 440-445, 2020
  22. 22.武藤哲史, 鈴木弘行. 第2章 7. 肺がん. よくわかるがん免疫療法ガイドブック-患者さんとご家族のために-. 金原出版株式会社. 76-84, 2020
  23. 23.武藤哲史, 山口光, 峯勇人, 髙木玄教, 尾崎有紀, 渡部晶之, 井上卓哉, 山浦匠, 福原光朗, 岡部直行, 松村勇輝, 長谷川剛生, 大杉純, 星野実加, 樋口光徳, 塩豊, 鈴木弘行. 特集 がん免疫療法のバイオマーカー探索 肺癌における腫瘍浸潤リンパ球の末梢血によるモニタリング. 癌と化学療法. 47(9): 1287-1291, 2020
  24. 24.鈴木弘行. 一枚のシェーマ 大動脈弓部・再建胃管浸潤肺癌の1切除例. 胸部外科. 73(12): 1006, 2020

ページの先頭へ戻る